Bank of England chief focused on tariff ‘growth shock’ but downplays UK recession risk

Bank of England chief focused on tariff ‘growth shock’ but downplays UK recession risk


Bank of England governor: We're seeing the uncertainty effect of tariffs

The Bank of England is focused on the potential U.K. growth shock from U.S. tariffs if there is a slowdown in global trade, the central bank’s governor Andrew Bailey said Thursday.

“We’re certainly quite focused on the growth shock,” Bailey told CNBC’s Sara Eisen in an interview at the IMF-World Bank Spring Meetings.

Going into its May 8 monetary policy meeting, the central bank will consider “arguments on both sides” around the impact of tariffs on growth and domestic supply constraints on inflation, Bailey said.

“There is clearly a growth issue we start with, with weak growth … but a big question mark is how much of that is caused by the weak demand, how much of it is caused by a weak supply side,” he continued.

“Because the weak supply side, of course, unfortunately, has the sort of the upside effect on inflation. So we’ve got to balance those two. But I think the trade issue is now the new part of that story.”

Inflation could be pulled in either direction by wider forces, with a redirection of trade exports into other markets being disinflationary, but a retaliation on U.S. tariffs by the U.K. government — which he stressed did not appear likely — pushing up inflation.

Bailey added that he did not see the U.K. as being close to a recession at present, but that it was clear economic uncertainty was weighing on business and consumer confidence.

IMF downgrade

The IMF earlier this week downgraded its 2025 growth forecast for the U.K. to 1.1% from 1.6%, citing the impact of U.S. President Donald Trump’s trade tariffs, higher borrowing costs and increased energy prices.

However, economic forecasting remains mired in uncertainty as countries engage in negotiations with U.S. officials over Trump’s swingeing universal tariff policy, currently on pause. The U.S. has imposed 25% tariffs on steel, aluminum and autos and a 10% levy on other British exports.

U.K. policymakers have expressed hopes of reaching a trade deal with the White House, with U.S. Vice President J. D. Vance saying there is a “good chance” of an agreement.

The Bank of England held interest rates at 4.5% at its March meeting, before Trump shocked the world with the scale of his tariff announcement.

Markets now see the BOE slashing rates to 4% by its August meeting as it grapples with a weaker growth outlook, along with a slowdown in inflation.



Source

U.S. and Iran haven’t backed ceasefire idea as Trump’s Hormuz Strait deadline nears
World

U.S. and Iran haven’t backed ceasefire idea as Trump’s Hormuz Strait deadline nears

US President Donald Trump disembarks from Air Force One upon arrival at Joint Base Andrews in Maryland, March 23, 2026. Saul Loeb | Afp | Getty Images President Donald Trump has not backed an idea for a 45-day ceasefire that would take effect before his upcoming deadline for Iran to either reopen the Strait of […]

Read More
S&P 500 rises as investors await possible Iran and U.S. ceasefire: Live updates
World

S&P 500 rises as investors await possible Iran and U.S. ceasefire: Live updates

Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell in New York on April 2, 2026. Charly Triballeau | Afp | Getty Images The S&P 500 rose on Monday following a winning week as oil prices pulled back, with traders weighing the odds that the U.S.-Iran war could […]

Read More
Neurocrine expands into metabolic diseases with .9 billion Soleno buyout
World

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout

Piotr Swiat | Lightrocket | Getty Images Neurocrine Biosciences will acquire rare-disease drugmaker ⁠Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused ​drugmaker’s expansion into ​metabolic disorders. The deal ​gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, […]

Read More